Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472290 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL9870336 | 0.98 | CYP1A2 (0.96) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL11544283 | 0.98 | CYP1A2 (0.96) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1127792 | 0.98 | CYP1A2 (0.96) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| SCHEMBL857572 | 0.98 | SMN1; SMN2 (0.95) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| Methane SCHEMBL11633126 | 0.96 | CYP1A2 (0.92) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| Bromide SCHEMBL11793837 | 0.95 | SMN1; SMN2 (0.91) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL946654 | 0.95 | SMN1; SMN2 (0.91) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| SCHEMBL2639576 | 0.93 | CYP1A2 (0.88) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| SCHEMBL547192 | 0.93 | CYP1A2 (0.88) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118005561-A | Preparation and application of ionizable lipid molecules of benzaldehyde framework | 浙江工业大学 | 2024-05-10 | — | — | CN | disclosed |
| CN-117843506-A | Lipid molecule for delivering active ingredients and application thereof | 中国科学院基础医学与肿瘤研究所(筹) | 2024-04-09 | — | — | CN | disclosed |
| CN-115286523-B | Lipid molecules for delivery of active ingredients and preparation and use of compositions thereof | 中国科学院基础医学与肿瘤研究所(筹) | 2024-03-19 | — | — | CN | disclosed |
| CN-117486738-A | Lipid molecule and composition thereof | 中国科学院基础医学与肿瘤研究所(筹) | 2024-02-02 | — | — | CN | disclosed |
| CN-115286523-A | Preparation and use of lipid molecules and compositions thereof for the delivery of active ingredients | 中国科学院基础医学与肿瘤研究所(筹) | 2022-11-04 | — | — | CN | disclosed |
| EP-2118067-B1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH SPA (IT) | 2013-05-08 | — | — | EP | disclosed |
| US-8163729-B2 | Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof | WYETH (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2323988-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | Wyeth LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010009290-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-2118067-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | Siena Biotech S.p.A. (IT) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008087529-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH S.P.A. (IT) | 2008-07-24 | — | — | WO | disclosed |
| US-20070238721-A1 | Highly Selective Novel Amidation Method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-11 | — | — | US | disclosed |
| EP-1753752-A1 | HIGHLY SELECTIVE NOVEL AMIDATION METHOD | Takeda Pharmaceutical Company Limited (JP) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005121133-A1 | HIGHLY SELECTIVE NOVEL AMIDATION METHOD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | CHRNA7, CHRNA2, CHRNA6 | SMN1; SMN2 2002/4885CYP1A2 1261/4885MAPK1 1781/4885 |
| US-20070238721-A1 | Highly Selective Novel Amidation Method | NAAA, CPS1, COASY | SMN1; SMN2 3439/4885CYP1A2 1660/4885MAPK1 4513/4885 |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | SMN1; SMN2 1693/4885CYP1A2 2584/4885MAPK1 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.